65 First-generation (eg, gefitinib and erlotinib) and second-generation (eg, afatinib and dacomitinib) EGFR TKIs have significantly improved PFS, and overall survival in the case of dacomitinib, ...

Background Data comparing systemic exposure and systemic vascular endothelial growth factor (VEGF) suppression of ranibizumab, bevacizumab and aflibercept following intravitreal injection are lacking.

Relacorilant in addition to nab-paclitaxel demonstrated a significant improvement in progression-free survival (PFS) and prolonged overall survival (OS) vs nab-paclitaxel monotherapy in patients with ...

Toripalimab induction therapy plus chemotherapy for 2 cycles, compared with chemotherapy alone, followed by definitive chemoradiotherapy and consolidation, led to significantly improved ...

On October 19, 2007, Herb Kohl, the chairman of the US Senate’s Special Committee on Aging, asked Genentech to clarify its decision to limit the availability of its product Avastin in favor of its ...

The addition of anlotinib to standard of care for newly diagnosed glioblastoma significantly improved PFS in a randomized phased 2 trial. However, OS did not differ between anlotinib and placebo arms.

This phase 3 trial — CAIRO6 (NCT02758951) — showed that perioperative systemic therapy improved progression-free survival (PFS) and disease-free survival (DFS) but not overall survival (OS).

One of these is Cimerli (ranibizumab-eqrn), an interchangeable biosimilar to Lucentis (ranibizumab) that was approved in August 2022. 2 Cimerli is used to treat several retinal disorders, including ...

1 Day PFS -1.14% DJIA -0.61% S&P Mid Cap 400 -0.18% Financial Services -0.47% ...

Xbrane re-submitted the BLA (Biologics License Application) for its investigational biosimilar candidate to LUCENTIS® (ranibizumab) to the FDA (US Food and Drug Administration) in December 2024.

Per Roche, the customized formulation of ranibizumab delivered by Susvimo is different from the ranibizumab intravitreal injection, which is marketed as Lucentis. Lucentis is also approved to ...

Susvimo was previously called the Port Delivery System with ranibizumab in the U.S. The customized formulation of ranibizumab delivered by Susvimo is different from the ranibizumab intravitreal ...